Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Serum soluble CD4, CD8 and IL-2R levels in adult acute myeloid leukemia in remission

Abstract

We have measured the serum levels of soluble CD4, CD8 and IL-2R in 43 patients with AML in complete remission (AML-CR). The sCD8 levels of AML-CR patients (443.9 ± 224.4 u/ml) were significantly high as compared to that of the normal controls (177.1 ± 76.3 u/ml),p < 0.01. The sIL-2R levels of AML-CR patients were 715.0 ± 646.3 u/ml, which significantly differed when compared to 322.1 ± 65.7 u/ml for the normal controls,p < 0.01. However, the sCD4 levels of AML-CR patients were 9.6 ± 4.7 u/ml, which did not differ from the 8.3 ± 2.6 u/ml of the normal controls. The AML-CR patients showed significantly increased sCD8 and sIL-2R levels at all ranges during the remission from one to 188 months.

The sCD8 levels and sIL-2R levels of the AML-CR patients showed a close correlation,p < 0.01. Further, the sCD8 levels and lymphokine activated killer cell cytotoxic activity showed a close correlation,p < 0.05. The presence of the activation of anti-tumor immunity may be related to the continuance of the remission in the AML-CR patients.

This is a preview of subscription content, log in to check access.

Abbreviations

IM:

infectious mononucleosis

AILD:

angio-immunoblastic lymphadenopathy

HD:

Hodgkin’s disease

HL:

hairy cell leukemia

AML:

acute myeloid leukemia

ALL:

acute lymphocytic leukemia

AML:

patients

AML:

pretreated patients

AML-CR:

patients with AML in complete remission

PMC:

peripheral mononuclear cells

NHL:

non-Hodgkin’s lymphoma

ATL:

adult T cell leukemia

NK-A:

natural killer cell cytotoxic activity

LAK-A:

lymphokine activated killer cell cytotoxic activity

References

  1. 1.

    Fujirnoto J, Levy S, Levy R: Spontaneous release of the Leu-2 (T8) molecule from human T cells.J Exp Med 159, 752 (1983).

  2. 2.

    Fujimoto J, Stewart S J, Levy R: Immunochemical analysis of the released Leu-2 (T8) molecule.J Exp Med 160, 116 (1984).

  3. 3.

    Rubin L A, Kurman C C, Fritz M E, Biddison W E, Boutin B, Yarchoan R, Nelson D L: Soluble interleukin 2 receptors are released from activated human cells in vivo.J Immunol 135, 3172 (1985).

  4. 4.

    Stein G, Alasevic J, Vinate F, Zanotti R, Chilosi M, Feller A C, Diamantstein T: Increased serum levels of soluble IL-2 receptor, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanism.Bri J Haematol 75, 485 (1990).

  5. 5.

    Tomkinson B E, Brown M C, Stephen H I P, Carrabis S. Sullivan J L: Soluble CD8 during T cell activation.J Immunol 142,2230 (1989).

  6. 6.

    Hsieh K H: Decreased production of CD8 (T8) antigen after immunotherapy.J Clin Immunol 9, 111 (1989).

  7. 7.

    Reddy M M, Lange M, Grieco M: Elevated soluble CD8 levels in sera of human immunodeficiency virus-infected population.J Clin Microbiol 27, 257 (1989).

  8. 8.

    Pui C H, Ip S H, Thompson E, Dodge R, Brown M, Wilimas J, Carrabis S, Kung P, Berard C W, Crist W M: Increased serum CD8 antigen level in childhood Hodgkin’s disease related to advanced stage and poor treatment outcome.Blood 73, 209 (1989).

  9. 9.

    Ho A D, Grossmann M, Knauf W, Martin H, Trumper L, Zwingers T, Sonnen R, Pralle H, Hunstein W: Plasma levels of CD8 antigen and interleukin-2 receptor antigen in patients with hairy ceil leukemia, relationship with splenectomy and with clinical response to therapy.Leukemia 3, 718 (1989).

  10. 10.

    Ho A D, Grossmann M, Trumper L, Pezzuto A, Pralle H, Boedewadt-Radzum S, Papendick U, God B, Zwingers T, Hunstein W: Clinical implications of increased plasma levels of CD8 in patients with hairy cell leukemia.Blood 75, 1119 (1990).

  11. 11.

    Pui C H, Schell M, Vodian M A, Kline S, Mirro J, Crist W M, Behm F: Serum CD4, CD8, and interleukin-2 receptor levels in childhood acute myeloid leukemia.Leukemia 5, 249 (1991).

  12. 12.

    Pui C H, Ip S H, Iflah S, Behm F G, Grose B H, Dodge R K, Crist W M, Furman W L, Murphy S B, Rivera G K: Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia.Blood 71, 1135 (1988).

  13. 13.

    Pui C H, Ip S H, Kung P, Dodge R K, Berard C W, Cnst W M, Murphy S B: High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin’s lymphoma.Blood 70, 624 (1987).

  14. 14.

    Steis R G, Marcon L, Clark J, Urba W, Longo D L, Neison D L, Maluish A E: Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia.Blood 77, 1304 (1988).

  15. 15.

    Motoi T, Uchiyama T, Uchino H, Ueda R, Araki K: Serum soluble interleukin-2 receptor levels in patients with adult T cell leukemia and human T-cell leukemia/lymphoma virus Type-I seropositive healthy carriers.Jpn J Cancer Res 79, 593 (1988).

  16. 16.

    Southern J T, Fallon J T, Dec G W, Jacobs D M, Cosimi A B, Brown M C, Kung P C, Colvin R B: A comparison of serum interleukin 2 receptor levels and endomyocardial biopsy grades in the monitoring of cardiac allograft rejection (abstract).J Heart Transpl 5, 370 (1986).

  17. 17.

    Dupere S, Obiri N, Lackey A, Emma D, Yannelli J, Orr D, Birch R, O’Connor T E: Patterns of cytokines related by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vivo.J Biol Resp Modi 9, 140 (1990).

  18. 18.

    Ohshima T, Takeuchi J: Short term intensive chemotherapy regimens for adult acute myeloid leukemia-DCMP-85 vs DBMP-85, in Kimura K, Yamada K, Frei E III, Catter S K (eds):Cancer Chemotherapy: Challenges for the future, p. 153. Excepta Medica, Japan (1988).

  19. 19.

    Takeuchi J, Endo M, Kanemaru M, Murakami J, Matsui K, Iizuka Y, Horikoshi A, Kitami I, Ohshima T: Short term intensive chemotherapy without maintenance for adult acute myeloid leukemia (AML) (abstract).Blood 76 (suppl 1), 325a (1990).

  20. 20.

    Bennet J M, Catovsky D, Daniel M T, Flandrin G, Galton D A G, Grainick G R, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia.Ann Intern Med 103, 620 (1985).

  21. 21.

    Iizuka Y, Sakurai T, Horikoshi A, Ohshima T: Inhibitory activity of interleukin 2-activated lymphocytes on human granulocyte precursors (CFU-g).Int J Cell Cloning 6, 146 (1988).

  22. 22.

    Dalgleish A G: The T4 molecule: function and structure.Immunol Today 7, 142 (1986).

  23. 23.

    Liu M A, Liu T: Effect of recombinant soluble CD4 on human peripheral blood lymphocyte responses in vitro.J Clin Invest 82, 2176 (1988).

  24. 24.

    Meuer S C, Schlossman S F, Reinherz E L: Clonal analysis of human cytotoxic T lymphocytes.Proc Natl Acad Sci USA 79, 4395 (1982).

Download references

Author information

Correspondence to Yoshikazu Iizuka or Masumi Aiso or Toshiteru Ohshima or Shigemasa Sawada or Takashi Horie.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Iizuka, Y., Aiso, M., Ohshima, T. et al. Serum soluble CD4, CD8 and IL-2R levels in adult acute myeloid leukemia in remission. Med Oncol. & Tumor Pharacother. 9, 57 (1992). https://doi.org/10.1007/BF02989655

Download citation

Key Words

  • sCD4
  • sCD8
  • SIL-2R
  • AML-CR